

Table S1. Severity of local and systemic adverse reactions in HIV-CORE 002.

Local AR	Severity				Severity				Severity				Severity						
pSG2.HIVconsv DNA	1	2	3	4	MVA.HIVconsv	1	2	3	4	ChAdV63.HIVconsv	1	2	3	4	Placebo	1	2	3	4
Pain/tenderness	6	0	0	0	Pain/tenderness	13	0	0	0	Pain/tenderness	8	0	0	0	Pain/tenderness	1	0	0	0
Pruritis	0	0	0	0	Pruritis	1	0	0	0	Pruritis	0	0	0	0	Pruritis	0	0	0	0
Skin reaction	12	0	0	0	Skin reaction	5	0	0	0	Skin reaction	7	0	0	0	Skin reaction	0	0	0	0
Systemic AR	Severity				Severity				Severity				Severity						
pSG2.HIVconsv DNA	1	2	3	4	MVA.HIVconsv	1	2	3	4	ChAdV63.HIVconsv	1	2	3	4	Placebo	1	2	3	4
allergic reaction	0	0	1	0	allergic reaction	0	0	0	0	allergic reaction	0	0	0	0	allergic reaction	0	0	0	0
chills/rigors	1	0	0	0	chills/rigors	4	0	0	0	chills/rigors	2	0	0	0	chills/rigors	0	0	0	0
fatigue/malaise	0	0	0	0	fatigue/malaise	2	0	0	0	fatigue/malaise	3	0	0	0	fatigue/malaise	1	0	0	0
pain/myalgia	1	0	0	0	pain/myalgia	7	0	0	0	pain/myalgia	7	0	0	0	pain/myalgia	0	0	0	0
headache	0	0	0	0	headache	0	0	0	0	headache	5	0	0	0	headache	0	0	0	0
fever	0	0	0	0	fever	9	0	0	0	fever	4	0	0	0	fever	0	0	0	0
					syncope	1	0	0	0	cough	1	0	0	0	vomit	0	1	0	0
					sore throat	1	0	0	0						stomach cramps	1	0	0	0

There were the following numbers of doses administered of each modality: pSG2.HIVconsv DNA 48, MVA.HIVconsv 23, ChAdV63.HIVconsv 2 low doses and 24 high doses, and placebo 23. Each dose was injected into two sites, one on each arm.